User profiles for Samira Fafi-Kremer
 | Fafi-Kremer SamiraVerified email at unistra.fr Cited by 18172 |
[HTML][HTML] Hepatitis C virus entry into hepatocytes: molecular mechanisms and targets for antiviral therapies
MB Zeisel, I Fofana, S Fafi-Kremer, TF Baumert - Journal of hepatology, 2011 - Elsevier
Hepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma.
Preventive modalities are absent and the current antiviral treatment is limited by resistance, …
Preventive modalities are absent and the current antiviral treatment is limited by resistance, …
[HTML][HTML] Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
…, L Courtellemont, H Péré, L Hocqueloux, S Fafi-Kremer… - Nature, 2021 - nature.com
The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India 1 , 2 , 3 , 4 – 5 .
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
Since then, it has become dominant in some regions of India and in the UK, and has spread to …
[HTML][HTML] Neurologic features in severe SARS-CoV-2 infection
…, O Collange, C Boulay, S Fafi-Kremer… - … England Journal of …, 2020 - Mass Medical Soc
Neurologic Features in SARS-CoV-2 Infection In a consecutive series of 64 patients with
Covid-19 and ARDS, 58 of whom underwent neurologic examination, severe agitation and …
Covid-19 and ARDS, 58 of whom underwent neurologic examination, severe agitation and …
[HTML][HTML] High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study
…, M Schenck, F Fagot Gandet, S Fafi-Kremer… - Intensive care …, 2020 - Springer
Purpose Little evidence of increased thrombotic risk is available in COVID-19 patients. Our
purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. Methods All …
purpose was to assess thrombotic risk in severe forms of SARS-CoV-2 infection. Methods All …
[HTML][HTML] Sensitivity of infectious SARS-CoV-2 B. 1.1. 7 and B. 1.351 variants to neutralizing antibodies
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) B.1.1.7 and B.1.351 variants
were first identified in the United Kingdom and South Africa, respectively, and have since …
were first identified in the United Kingdom and South Africa, respectively, and have since …
Brain MRI findings in severe COVID-19: a retrospective observational study
…, Y Hansmann, PM Mertes, F Schneider, S Fafi-Kremer… - Radiology, 2020 - pubs.rsna.org
Background Brain MRI parenchymal signal abnormalities have been associated with
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Purpose To describe the …
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Purpose To describe the …
Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses
…, P Perrin, J Olagne, N Cognard, S Fafi-Kremer… - Jama, 2021 - jamanetwork.com
Methods| All kidney transplant recipients followed up in the outpatient Kidney Transplantation
Department of Strasbourg University Hospital between January 20, 2021, and June 3, …
Department of Strasbourg University Hospital between January 20, 2021, and June 3, …
[HTML][HTML] Delirium and encephalopathy in severe COVID-19: a cohort analysis of ICU patients
…, C Kummerlen, A Monnier, C Boulay, S Fafi-Kremer… - Critical care, 2020 - Springer
Background Neurotropism of SARS-CoV-2 and its neurological manifestations have now
been confirmed. We aimed at describing delirium and neurological symptoms of COVID-19 in …
been confirmed. We aimed at describing delirium and neurological symptoms of COVID-19 in …
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
B-cell posttransplantation lymphoproliferative disorder (B-PTLD) is a rare but severe complication
of transplantation, with no consensus on best treatment practice. This prospective trial, …
of transplantation, with no consensus on best treatment practice. This prospective trial, …
Development of hepatitis C virus vaccines: challenges and progress
F Stoll-Keller, H Barth, S Fafi-Kremer… - Expert Review of …, 2009 - Taylor & Francis
Development of an effective vaccine against the hepatitis C virus (HCV) has long been
defined as a difficult challenge due to the considerable variability of this RNA virus and the …
defined as a difficult challenge due to the considerable variability of this RNA virus and the …